Calcineurin Inhibitor Withdrawal After Renal Transplantation with Alemtuzumab: Clinical Outcomes and Effect on T-Regulatory CellsArticle Published on 2024-06-202024-09-05 Journal: American journal of transplantation : official jou [Category] update2024, [키워드] Alemtuzumab calcineurin inhibitor agents calculated glomerular filtration rate Campath-1H CD4+CD25+ T cells chronic nephrotoxicity clinical kidney transplantation CNI nephrotoxicity FOXP3 immunosuppression withdrawal T-regulatory cells [DOI] 10.1111/j.1600-6143.2008.02260.x PMC 바로가기 [Article Type] Article
Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis다발성 경화증에서 SARS-CoV-2 백신 접종에 대한 면역 반응: 체계적인 검토/메타 분석Review Published on 2022-08-012022-09-11 Journal: Annals of Clinical and Translational Neurology [Category] COVID19(2023년), SARS, 치료기술, [키워드] Acetate Affect Alemtuzumab anti-CD20 Antibody detection Antibody Response Antibody responses Antibody testing applied CD20 cellular response Cellular responses Cladribine demonstrated dimethyl fumarate Epidemiology fumarate Glatiramer Glatiramer acetate Google Scholar HCs healthy control immune response Immunity inactivated independent interferon Interferon-beta mAb mAbs Meta-analysis meta-analysis and systematic review monoclonal antibody MOOSE mRNA mRNA vaccine mRNA vaccines multivariate logistic regression multivariate logistic regression model Natalizumab not affect observational studies observational study Odds ratio Patient positive predict response SARS-CoV-2 infections SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines searched seroconversion rate seroconversion rates sphingosine-1-phosphate systematic review T cell T cell response T-cell Response T-cell responses Teriflunomide therapy Vaccine vaccine immunity vaccine response Vaccines vector virus [DOI] 10.1002/acn3.51628 PMC 바로가기 [Article Type] Review
Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)article Published on 2022-04-012024-09-02 Journal: Arthritis Research & Therapy [Category] 대상포진, [키워드] Alemtuzumab ANCA Behcet’s disease clinical trial Lymphocytes T cells Vasculitis [DOI] 10.1186/s13075-022-02761-6 PMC 바로가기 [Article Type] article
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical ViewpointCovid-19 Pandemic 동안 다발성 경화증 치료에 사용되는 약물 : 중요한 관점Article Published on 2022-01-012022-08-31 Journal: Current neuropharmacology [Category] SARS, 치료제, [키워드] Acetate activating acute respiratory distress acute respiratory distress syndrome Alemtuzumab analogue antiviral activity approved ARDS autoimmune disorder Autoimmune disorders caution cellular Cladribine concern COVID-19 COVID-19 infection COVID-19 pandemic cytokine Cytokine storm Defense depleting detrimental dimethyl fumarate disease Disease-modifying therapy drug early stage endothelial example fingolimod fumarate Glatiramer Glatiramer acetate health problem hyperinflammation Hyperinflammatory IFN IFNs immunomodulation interfere interferon Invasion lung Macrophage mechanisms Multiple multiple sclerosis Natalizumab neuroprotection Nrf-2 nucleotide nucleotides Ocrelizumab other organs overcome oxidative stress pathway potential risk Protective public health raised reinforcement respiratory distress risk risk-benefit ratio. Safe SARS-CoV-2 SARS-COV-2 infection sclerosis suggested syndrome Teriflunomide Treatment Viral viral replication [DOI] 10.2174/1570159X19666210330094017 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies다양한 질병 조절 요법으로 치료받는 다발성 경화증 환자에서 mRNA COVID-19 백신의 면역원성과 안전성Article Published on 2022-01-012022-09-11 Journal: Neurotherapeutics : the journal of the American So [Category] SARS, 진단, 치료기술, [키워드] Alemtuzumab Cladribine correlation COVID-19 COVID-19 vaccination detect develop Disease-modifying therapies drugs evaluated fatigue fingolimod Hospitalization humoral humoral immune response Humoral response IgG immune response immunoassay immunogenicity injection injection site Microparticle MONITOR mRNA COVID-19 vaccine mRNA COVID-19 vaccines Multiple multiple sclerosis Natalizumab Ocrelizumab Pain Patient patients treated positively correlated reduce reported Safe SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 nucleoprotein second dose Side effect significantly lower therapy treated Treatment vaccination was tested [DOI] 10.1007/s13311-021-01165-9 PMC 바로가기 [Article Type] Article
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey다발성 경화증 치료 및 관리에 대한 COVID-19의 영향: 유럽 다발성 경화증 치료 및 연구 위원회의 결과Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] SARS, 치료기술, [키워드] Access to care activated adopted Alemtuzumab anti-CD20 Care CD20 changes in Cladribine Clinical practice Committee coronavirus disease Coronavirus disease-19 country COVID-19 COVID-19 emergency dimethyl fumarate disease-modifying treatment Emergency Europe European fingolimod fumarate Glatiramer Impact interferons lymphopenia management Modification Multiple multiple sclerosis Natalizumab overcome Patient promoted reported Result Safe sclerosis Spread Telemedicine Teriflunomide therapy Treatment unique with COVID-19 [DOI] 10.1177/13524585211005339 PMC 바로가기 [Article Type] Article
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosisocrelizumab, alemtuzumab 및 cladribine 후 CD19 B 세포 재증식: 다발성 경화증에서 SARS-CoV-2 예방 접종에 대한 의미Article Published on 2022-01-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] SARS, 진단, [키워드] Alemtuzumab B cell B-cell CD19 CD20 Cladribine clinical trial Control Controlled determine dosing interval exhibited extension facilitate Frequency inhibit lymphocyte maintain MOST Multiple multiple sclerosis occurred Ocrelizumab Relapse relapsing rituximab SARS-CoV-2 vaccination Seroconversion seroconvert Standard therapy Tablet Treatment Trial vaccination [DOI] 10.1016/j.msard.2021.103448 PMC 바로가기 [Article Type] Article
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study화이자 BNT162b2 코로나19 백신 접종 후 다발성 경화증 환자의 체액성 면역 반응: 최대 6개월 단면 연구Observational Study Published on 2021-12-152022-09-12 Journal: Journal of neuroimmunology [Category] MERS, SARS, 임상, 진단, [키워드] Alemtuzumab Appropriate Cladribine COVID-19 COVID-19 vaccination COVID19 cross-sectional demonstrated dimethyl fumarate Disease modifying treatments fingolimod healthy subject healthy subjects help Humoral immunity IgG IgG antibody IgG response immune response Multiple multiple sclerosis Natalizumab Ocrelizumab Patient response Teriflunomide treated treated patients Treatment vaccination Vaccine [DOI] 10.1016/j.jneuroim.2021.577746 PMC 바로가기 [Article Type] Observational Study
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients사르데냐 다발성 경화증 환자에서 BNT162b2 백신에 대한 체액 반응에 대한 다양한 질병 수정 요법의 효과Immunology Published on 2021-12-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료법, [키워드] Acetate addition affected age Alemtuzumab analyzed anti-SARS-CoV-2 vaccine Antibody titer Antibody titers BNT162b2 BNT162b2 vaccine Clinical data clinically COVID-19 COVID-19 vaccine demographic difference dimethyl fumarate Disease-modifying therapy drug Effect Factor fingolimod followed by fumarate Glatiramer healthy control humoral immune response Humoral immunity Humoral response immune response infected with SARS-CoV-2 interferon investigated linear Male sex mixed-effects model mRNA mRNA-based Multiple multiple sclerosis objective observé of BNT162b2 Older age Patient patients patients treated Prevent response Result Sardinian SARS-CoV-2 SARS-COV-2 infection sclerosis second dose sera serology Sex significantly significantly higher significantly lower smoking smoking status statistically significant difference Teriflunomide tested therapy Treatment treatment group treatment groups uninfected untreated patients vaccination Vaccine vaccine efficacy were assessed [DOI] 10.3389/fimmu.2021.781843 PMC 바로가기 [Article Type] Immunology
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing dataShort Report Published on 2021-12-092024-09-04 Journal: Multiple Sclerosis Journal [Category] 대상포진, [키워드] Alemtuzumab Autoimmunity multiple sclerosis Post-marketing product surveillance Risk assessment Treatment outcome [DOI] 10.1177/13524585211061335 PMC 바로가기 [Article Type] Short Report